Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Sudden unexpected death on fingolimod.

× No keyword cloud information.

19 in total

1. VBP15, a novel anti-inflammatory, is effective at reducing the severity of murine experimental autoimmune encephalomyelitis.

Authors: Blythe C Dillingham; Susan M Knoblach; Gina M Many; Brennan T Harmon; Amanda M Mullen; Christopher R Heier; Luca Bello; John M McCall; Eric P Hoffman; Edward M Connor; Kanneboyina Nagaraju; Erica K M Reeves; Jesse M Damsker
Journal: Cell Mol Neurobiol Date: 2014-11-13 Impact factor: 5.046

2. Fingolimod and cardiac risk: latest findings and clinical implications.

Authors: Wendy S Vargas; Jai S Perumal
Journal: Ther Adv Drug Saf Date: 2013-06

Review 3. Sphingosine 1-Phosphate Receptor Modulators for the Treatment of Multiple Sclerosis.

Authors: Burhan Z Chaudhry; Jeffrey A Cohen; Devon S Conway
Journal: Neurotherapeutics Date: 2017-10 Impact factor: 7.620

Review 4. A review of possible therapies for multiple sclerosis.

Authors: Hui Li; Gaojian Lian; Guang Wang; Qianmei Yin; Zehong Su
Journal: Mol Cell Biochem Date: 2021-04-22 Impact factor: 3.396

Review 5. Risk stratification and mitigation multiple sclerosis.

Authors: Daniel Ontaneda; Samuel Cohn; RobertJ Fox
Journal: Mult Scler Relat Disord Date: 2014-09 Impact factor: 4.339

Review 6. Mechanism and adverse effects of multiple sclerosis drugs: a review article. Part 1.

Authors: Aryan Rafiee Zadeh; Mozhde Askari; Niloufar Nasr Azadani; Akram Ataei; Keyvan Ghadimi; Nooshin Tavoosi; Masih Falahatian
Journal: Int J Physiol Pathophysiol Pharmacol Date: 2019-08-15

Review 7. Optimizing the initial choice and timing of therapy in relapsing-remitting multiple sclerosis.

Authors: Rebecca S Farber; Ilana K Sand
Journal: Ther Adv Neurol Disord Date: 2015-09 Impact factor: 6.570

Review 8. Adaptive immune responses in CNS autoimmune disease: mechanisms and therapeutic opportunities.

Authors: Rhoanne C McPherson; Stephen M Anderton
Journal: J Neuroimmune Pharmacol Date: 2013-04-09 Impact factor: 4.147

9. Epigallocatechin-3-gallate: a useful, effective and safe clinical approach for targeted prevention and individualised treatment of neurological diseases?

Authors: Anja Mähler; Silvia Mandel; Mario Lorenz; Urs Ruegg; Erich E Wanker; Michael Boschmann; Friedemann Paul
Journal: EPMA J Date: 2013-02-18 Impact factor: 6.543

Review 10. An update on immunopathogenesis, diagnosis, and treatment of multiple sclerosis.

Authors: Neeta Garg; Thomas W Smith
Journal: Brain Behav Date: 2015-08-03 Impact factor: 2.708